Glioma Panel
This Glioma Panel examines specific genetic alterations in glioma tumors, including 1P/19Q codeletion, IDH1/2 mutations, and MGMT promoter methylation. These molecular markers influence glioma prognosis and response to treatment. The panel helps determine the most effective therapy options for glioma patients.
Glioma Panel Package in Vadodara Overview
What is Glioma Panel test?
Glioma Panel is a focused molecular test set that evaluates three cornerstone biomarkers in diffuse gliomas: 1p/19q codeletion, IDH1/2 mutations, and MGMT promoter methylation, to refine diagnosis, prognosis, and treatment planning in line with modern integrated classifications.
Why consider Glioma Panel test?
- Improves diagnostic accuracy beyond histology by distinguishing oligodendroglioma from astrocytoma and stratifying glioblastoma biology, which impacts prognosis and therapy choices.
- Provides predictive information: MGMT promoter methylation is associated with better response to alkylating chemotherapy (e.g., temozolomide), particularly relevant in high‑grade and elderly glioma settings.
Who should get tested for Glioma Panel test?
- Patients with newly diagnosed diffuse gliomas or glioblastoma where integrated histo‑molecular classification is needed to guide management and clinical trial eligibility.
- Patients with limited prior profiling or recurrent tumors where clarifying IDH status, confirming 1p/19q, and establishing MGMT methylation can influence second‑line strategies.
More Information about Glioma Panel test
OTHER NAMES: Glioma Core Molecular Panel, Glioma Marker Panel
Glioma is a primary tumor of glial cells in the brain and spinal cord, now classified primarily by molecular markers alongside histology, especially IDH mutation status and 1p/19q codeletion in adults. Modern classification separates adult diffuse gliomas into IDH‑mutant astrocytoma, IDH‑mutant and 1p/19q‑codeleted oligodendroglioma, and IDH‑wildtype glioblastoma, which differ in prognosis and therapy response.
No special preparations needed
- Request Letter
- Specimen
- Block Indentification Number
- Number Of Observers
- Total Number Of Cells Analysed
- Deletion 1p
- Loss Of Chromosome 1
- Normal
- Interpretation (1p)
- Total Number Of Cells Analysed
- Deletion 19
- Loss Of Chromosome 19
- Normal
- Interpretation (19q)
- Interpretation
- Mgmt Promoter Methylation
- Idh1 And Idh2 Gene Mutation Detection
Test code
4551
Specimen vol. and vacutainer information
| Specimen | Vacutainer | Volume |
|---|---|---|
| Edta Whole Blood | Lavender Vacutainer | 2 ML |
| Paraffin Block | Others | 10 ml |
| Plasma Cit.frozen | Blue Vacutainer | 1 ML |
Specimen stability information
Paraffin Block
Collection instructions
Formalin-fixed (10% buffered formalin for 24-48 hrs), paraffin-embedded (FFPE) tissue specimens. Transport tissue block or 3 unstained slides/ sample (4-micron thick sections) containing malignant tissue on positively charged slides. * Time and duration of fixation should be mentioned on the TRF.* Required clinical details, include surgical pathology report.
Specimen rejection criteria
Test run frequency
'
Turn around time
8 Working Days
Performing locations
Department
- Advanced Molecular Diagnostics R&d
- Cytogenetics
CPT and Loinc codes
Package price
₹20000
Need Help?
Talk to our health experts for guidance on tests, reports, or bookings.
WhatsApp to Book TestGlioma Panel
₹20000